For this clinical hair loss guide, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.
A friend of mine, Alex, a 31-year-old software engineer in Austin, texted me a photo of his shower drain last October. Clump of hair, maybe fifty strands. “Is this normal or am I going bald?” He’d been working 70-hour weeks for three months straight, sleeping five hours a night, and had just come off a nasty bout of COVID. The honest answer was: it depends entirely on which kind of hair loss this is. And that distinction, which most guys never learn, is the whole ballgame.
The Norwood scale is the standard dermatology classification system for male pattern hair loss: seven main stages plus several variant subtypes, developed by O’Tar Norwood in 1975 as an extension of James Hamilton’s 1951 work. It remains the most widely used staging tool in both clinical practice and research. But before you can place yourself on that scale, you need to know whether your hair loss even belongs on it. Telogen effluvium (the stress-shedding kind) and androgenetic alopecia (the genetic kind) share a symptom, and that’s about where the overlap ends.
This article covers what a dermatology evaluation would, with one focus: practical strategies for self-identifying your Norwood stage from standardized photos, and knowing when what you’re seeing isn’t pattern loss at all.
Two Types of Loss, Two Completely Different Problems
Here’s the simplest way to think about it. Androgenetic alopecia is a slow siege. Telogen effluvium is a sudden flood.
Pattern hair loss centers on dihydrotestosterone (DHT), a potent androgen produced from testosterone by the 5-alpha reductase enzyme. In genetically susceptible follicles, DHT binds to the androgen receptor in the dermal papilla and, across successive hair growth cycles, shortens the anagen (growth) phase, lengthens the telogen (resting) phase, and physically shrinks the dermal papilla. The visible result is follicular miniaturization: hairs that previously grew thick and long become progressively thinner, shorter, and eventually nonpigmented vellus hairs. You don’t wake up one morning and notice it. It creeps.
The genetics are polygenic. The androgen receptor gene on the X chromosome is one documented locus (which is why the maternal grandfather gets blamed), but the paternal side and other autosomal loci contribute meaningfully. Family history is a useful hint, not a verdict.
Telogen effluvium is a different animal entirely. A severe stressor, illness, surgery, crash diet, emotional trauma, hormonal shift, pushes a large percentage of follicles into the resting phase simultaneously. Two to three months later, they all shed at once. It looks terrifying. But the follicles aren’t damaged. They’re just on a synchronized schedule that normally wouldn’t happen. In most cases, full regrowth occurs within six to nine months after the stressor resolves.
The catch is that telogen effluvium can unmask early androgenetic alopecia that was already underway. Alex’s situation, as it turned out, was both. The COVID and sleep deprivation triggered a telogen shed, but once that resolved, the hairline recession that had been quietly progressing became more obvious.
How Dermatologists Actually Tell Them Apart
The American Academy of Dermatology’s clinical guidelines for hair loss evaluation emphasize a structured approach beyond visual pattern recognition. A complete workup typically includes patient history, family history, scalp examination, trichoscopy (dermoscopy of the scalp), and selective laboratory testing.
History is where the diagnosis often starts. Timeline matters enormously. Did the shedding begin suddenly, with diffuse thinning everywhere, two to three months after a specific event? That points toward telogen effluvium. Has the hairline been slowly receding at the temples over years, with gradual thinning at the crown? Classic androgenetic alopecia.
Trichoscopy adds resolution the unaided eye cannot match. In androgenetic alopecia, characteristic findings include hair shaft diameter variability (caliber variability of 20% or more), yellow dots representing empty follicular ostia, and decreased follicular unit density in affected areas with preservation of the occipital donor zone.
Laboratory testing is selective, not routine. Ferritin, thyroid stimulating hormone, vitamin D, and complete blood count are reasonable when telogen effluvium is suspected or in patients with diffuse thinning. The AAD does not recommend androgen panels routinely in men with classic pattern loss. The diagnosis is clinical.
Standardized photography supports both diagnosis and tracking. Front, top, sides, and back views taken at consistent distance and lighting, with the head held in a reproducible position, allow meaningful before-and-after comparisons over months. (Most selfie-based assessments are useless because the angle and lighting change every time. Consistency is the whole point.)
A useful complement to dermatology evaluation is this clinical hair loss guide, which provides the detailed Norwood staging reference and assessment workflow used in the dermatology literature.
What Actually Works for Pattern Loss (and What the Evidence Says)
Treatment of pattern hair loss is most effective when started early, before significant follicular loss has occurred. Here’s what the evidence supports, roughly ordered by strength of data.
Oral finasteride 1 mg daily has the largest evidence base. The original five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 showed sustained improvements in hair count and patient self-assessment versus placebo. Sexual dysfunction, the most discussed side effect, affects a small percentage of users in randomized trials and is generally reversible on discontinuation.
Topical minoxidil 5% applied twice daily is FDA-approved for over-the-counter use. The mechanism isn’t fully understood but appears to involve potassium channel opening, vasodilation, and a direct effect on the hair follicle that prolongs anagen. Response typically becomes visible at three to six months. Foam and solution formulations are clinically equivalent. Roughly 40 to 60 percent of users see visible improvement in randomized trials, with nonresponse partly explained by individual variation in sulfotransferase enzyme activity.
Low-dose oral minoxidil (0.25 to 5 mg daily) is increasingly used off-label. A 2021 multicenter study by Vañó-Galván et al. in JAAD documented efficacy at lower doses than the original cardiovascular formulation, with a more manageable side-effect profile than originally feared. Periorbital edema and hypertrichosis are reported.
Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, lowering DHT more aggressively than finasteride. Head-to-head trials have associated it with larger hair density improvements. It’s approved for benign prostatic hypertrophy and used off-label for hair loss.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable findings. Reasonable additions to medical therapy in selected patients, but not substitutes.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles from the donor zone to recipient areas. Most appropriate when the loss pattern is stable and donor capacity is adequate. Transplanted follicles generally retain their genetic resistance to miniaturization, but surrounding native hair may continue thinning, which is why most patients continue medical therapy post-transplant.
The Money Part
Let’s be blunt about costs, because they matter.
Generic oral finasteride 1 mg runs $10 to $25 per month at US pharmacies with common discount cards, sometimes $5 to $15 through direct-to-consumer telehealth. Branded Propecia costs $70 to $90 monthly with no documented clinical advantage. (This is one of those situations where the generic is identical and the brand premium buys you nothing but a nicer box.)
Generic topical minoxidil 5%: $10 to $30 per month. Branded Rogaine: roughly double.
Low-dose oral minoxidil in generic form is often under $15 per month. The real cost driver is the prescribing visit ($50 to $150 through telehealth, or covered by insurance through a routine dermatology visit).
Hair transplantation in the US typically costs $4 to $10 per graft for FUE. A typical 2,500 to 3,500 graft case puts total cost at $10,000 to $35,000. In Turkey, similar graft counts run $2,000 to $5,000 total, reflecting differences in labor costs and clinic overhead rather than necessarily quality differences.
PRP runs $500 to $1,500 per session, with most protocols recommending three to four sessions in the first year plus maintenance. The total first-year cost can equal or exceed an entire year of combination medical therapy.
Insurance generally does not cover pattern hair loss treatment (classified as cosmetic). HSA and FSA accounts may cover prescribed medications and physician visits but typically not surgical procedures.
The Lifestyle Factors That Actually Matter (and the Ones That Don’t)
Pattern hair loss is genetically determined. Full stop. But several lifestyle factors influence the rate of progression and overall hair health, and the peer-reviewed literature (primarily JAAD and the International Journal of Trichology) supports a few clear conclusions.
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus nonsmokers in matched populations.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding through telogen effluvium mechanisms. Iron repletion in deficient patients reduces shedding. Iron supplementation in iron-replete patients does nothing for hair density.
Severe acute stress can precipitate telogen effluvium beginning two to three months after the event. It typically resolves within six to nine months once the stressor abates.
Anabolic steroid use accelerates pattern hair loss in genetically susceptible men through supraphysiologic androgen exposure, with effects that may not be fully reversible after discontinuation.
Severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. Modest dietary improvements do not produce visible hair benefits beyond addressing specific deficiencies. The boring truth is that no superfood regrows hair.
When You Need to See a Dermatologist in Person
Self-management is reasonable in many cases, but several scenarios warrant in-person evaluation rather than telehealth or online tools:
Sudden, diffuse shedding within the last six months (suggests telogen effluvium requiring workup of the precipitating event). Patchy loss with smooth, well-circumscribed bald patches (suggests alopecia areata, an autoimmune condition with a different treatment pathway). Loss accompanied by scalp pain, burning, redness, scaling, or visible scarring (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, which requires prompt diagnosis to halt permanent follicular destruction). Hair loss in women with menstrual irregularities, acne, or hirsutism (warrants endocrine evaluation for PCOS or other androgen excess states). Rapid progression (more than one Norwood stage per year) in a young patient. Failure to respond to documented use of standard medical therapy over 12 months.
The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for consultation. I’d add my own take: if you’re Googling hair loss at 2 AM, you’ve already crossed that threshold. Just go.
FAQs
Is the Norwood scale used for women?
No. The Norwood scale is designed for male pattern hair loss. Female pattern hair loss is typically classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Should I get a hair transplant if I am in my 20s?
Experienced surgeons approach transplantation in patients in their 20s cautiously because the long-term progression pattern isn’t established yet. Medical therapy to stabilize native hair is usually prioritized first.
How accurate are AI hair-loss assessment tools?
They provide reasonable orientation for self-screening but do not replace dermatologic evaluation. Best used as a starting point for understanding likely stage and treatment options.
Does minoxidil work for everyone?
Minoxidil produces visible improvement in roughly 40 to 60 percent of users in randomized trials, with response emerging at three to six months. A subset of patients lack sufficient sulfotransferase activation, which partly explains nonresponse.
Are hair transplants permanent?
Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. Surrounding native hair may continue to thin, which is why most patients continue medical therapy after transplantation.
Is hair loss covered by insurance?
Pattern hair loss treatment is generally classified as cosmetic and not covered. Some HSA and FSA accounts will cover prescribed medications and physician visits.
Can telogen effluvium become permanent?
In rare cases, chronic telogen effluvium (lasting longer than six months) can persist, though it typically does not cause permanent hair loss. If the underlying trigger is identified and resolved, regrowth is expected.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
